



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/641,802	08/17/2000	Istvan Boldogh	265.00240101	5387

7590 06/18/2002

Mueting Raasch & Gebhardt PA  
PO Box 581415  
Minneapolis, MN 55458-1415

EXAMINER

HAYES, ROBERT CLINTON

ART UNIT

PAPER NUMBER

1647

DATE MAILED: 06/18/2002

7

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/641,802

Applicant(s)

BOLDOGH ET AL.

Examiner

Robert Hayes  
Elizabeth C. Kemmerer, Ph.D.

Art Unit

1648 7

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 25 July 2001.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-15 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-15 are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_ 6) ☐ Other: \_\_\_\_\_

**DETAILED ACTION**

***Election/Restrictions***

Restriction to one of the following inventions is required under 35 U.S.C. 121:

1. Claims 1-8 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 1, classified in class 435, subclass 325, for example.
2. Claims 1-8 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 2, classified in class 435, subclass 325, for example.
3. Claims 1-8 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 3, classified in class 435, subclass 325, for example.
4. Claims 1-8 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 4, classified in class 435, subclass 325, for example.
5. Claims 1-8 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 5, classified in class 435, subclass 325, for example.
6. Claims 1-8 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 6, classified in class 435, subclass 325, for example.

Art Unit: 1646

7. Claims 1-8 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 7, classified in class 435, subclass 325, for example.
8. Claims 1-8 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 8, classified in class 435, subclass 325, for example.
9. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 9, classified in class 435, subclass 325, for example.
10. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 10, classified in class 435, subclass 325, for example.
11. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 11, classified in class 435, subclass 325, for example.
12. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 12, classified in class 435, subclass 325, for example.
13. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 13, classified in class 435, subclass 325, for example.

14. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 14, classified in class 435, subclass 325, for example.
15. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 15, classified in class 435, subclass 325, for example.
16. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 16, classified in class 435, subclass 325, for example.
17. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 17, classified in class 435, subclass 325, for example.
18. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 18, classified in class 435, subclass 325, for example.
19. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 19, classified in class 435, subclass 325, for example.
20. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 20, classified in class 435, subclass 325, for example.

Art Unit: 1646

21. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 21, classified in class 435, subclass 325, for example.
22. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 22, classified in class 435, subclass 325, for example.
23. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 23, classified in class 435, subclass 325, for example.
24. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 24, classified in class 435, subclass 325, for example.
25. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 25, classified in class 435, subclass 325, for example.
26. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 26, classified in class 435, subclass 325, for example.
27. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 27, classified in class 435, subclass 325, for example.

28. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 28, classified in class 435, subclass 325, for example.
29. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 29, classified in class 435, subclass 325, for example.
30. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 30, classified in class 435, subclass 325, for example.
31. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 31, classified in class 435, subclass 325, for example.
32. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 32, classified in class 435, subclass 325, for example.
33. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 33, classified in class 435, subclass 325, for example.
34. Claims 1-7 and 14, each in part, drawn to methods of contacting cells in vitro with SEQ ID NO: 34, classified in class 435, subclass 325, for example.

35. Claims 1-8 and 14, each in part, drawn to methods of contacting cells in vitro with one specific combination of SEQ ID NOs: 1-34 (Applicant must specify one particular combination), classified in class 435, subclass 325, for example.
36. Claims 1-15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 1, classified in class 514, subclass 2, for example.
37. Claims 1-15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 2, classified in class 514, subclass 2, for example.
38. Claims 1-15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 3, classified in class 514, subclass 2, for example.
39. Claims 1-15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 4, classified in class 514, subclass 2, for example.
40. Claims 1-15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 5, classified in class 514, subclass 2, for example.
41. Claims 1-15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 6, classified in class 514, subclass 2, for example.
42. Claims 1-15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 7, classified in class 514, subclass 2, for example.
43. Claims 1-15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 8, classified in class 514, subclass 2, for example.



44. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 9, classified in class 514, subclass 2, for example.
45. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 10, classified in class 514, subclass 2, for example.
46. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 11, classified in class 514, subclass 2, for example.
47. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 12, classified in class 514, subclass 2, for example.
48. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 13, classified in class 514, subclass 2, for example.
49. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 14, classified in class 514, subclass 2, for example.
50. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 15, classified in class 514, subclass 2, for example.

51. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 16, classified in class 514, subclass 2, for example.
52. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 17, classified in class 514, subclass 2, for example.
53. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 18, classified in class 514, subclass 2, for example.
54. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 19, classified in class 514, subclass 2, for example.
55. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 20, classified in class 514, subclass 2, for example.
56. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 21, classified in class 514, subclass 2, for example.
57. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 22, classified in class 514, subclass 2, for example.

Art Unit: 1646

58. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 23, classified in class 514, subclass 2, for example.
59. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 24, classified in class 514, subclass 2, for example.
60. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 25, classified in class 514, subclass 2, for example.
61. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 26, classified in class 514, subclass 2, for example.
62. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 27, classified in class 514, subclass 2, for example.
63. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 28, classified in class 514, subclass 2, for example.
64. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 29, classified in class 514, subclass 2, for example.

Art Unit: 1646

65. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 30, classified in class 514, subclass 2, for example.
66. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 31, classified in class 514, subclass 2, for example.
67. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 32, classified in class 514, subclass 2, for example.
68. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 33, classified in class 514, subclass 2, for example.
69. Claims 1-7, 9-12, 14 and 15, each in part, drawn to methods of contacting cells in vivo with SEQ ID NO: 34, classified in class 514, subclass 2, for example.
70. Claims 1-15, each in part, drawn to methods of contacting cells in vivo with a specific combination of SEQ ID NOs: 1-34 (Applicant must specify one particular combination), classified in class 514, subclass 2, for example.

The inventions are distinct, each from the other because of the following reasons:

Although there are no provisions under the section for "Relationship of Inventions" in M.P.E.P. § 806.05 for inventive groups that are directed to different

Art Unit: 1646

methods, restriction is deemed to be proper because these methods appear to constitute patentably distinct inventions for the following reasons: Groups 1-70 are directed to methods that are distinct both physically and functionally, and are not required one for the other. Inventions 1-35 requires search and consideration of in vitro cell culturing method steps, which is not required by the in vivo Inventions 36-70. Furthermore, contacting cells with each of the 34 peptides, or a particular combination thereof, requires a separate and non-overlapping search of the literature and sequence databases. Therefore, a search and examination of all of the methods in one patent application would result in an undue burden, since the searches for the methods are not co-extensive, the classification is different, and the subject matter is divergent.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, separate search requirements, and different classification, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim


Art Unit: 1646

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert Hayes, Ph.D., whose telephone number is (703) 305-3132.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz, Ph.D., can be reached on (703) 308-4623. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.



ECK  
June 17, 2002

ELIZABETH KEMMERER  
PRIMARY EXAMINER